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Abstract
The mitochondrial flavoprotein ferredoxin reductase (FDXR) is required for biogenesis of iron–sulfur clusters and for
steroidogenesis. Iron–sulfur (Fe–S) clusters are ubiquitous cofactors essential to various cellular processes, and an
increasing number of disorders are associated with disruptions in the synthesis of Fe–S clusters. Our previous studies
have demonstrated that hypomorphic mutations in FDXR cause a novel mitochondriopathy and optic atrophy in
humans and mice, attributed in part to reduced function of the electron transport chain (ETC) as well as elevated
production of reactive oxygen species (ROS). Inflammation and peripheral neuropathy are also hallmarks of this
disease. In this paper, we demonstrate that FDXR mutation leads to significant optic transport defects that are likely to
underlie optic atrophy, a major clinical presentation in FDXR patients, as well as a neurodegenerative loss of cells in the
central nervous system (CNS). Molecular analysis indicates that FDXR mutation also leads to mitochondrial iron
overload and an associated depolarization of the mitochondrial membrane, further supporting the hypothesis that
FDXR mutations cause neurodegeneration by affecting FDXR’s critical role in iron homeostasis.
Introduction
Iron overload is a frequently observed occurrence in
many mitochondrial diseases, as well as a common cause
for neurological disorders. Iron is essential for many cel-
lular and biochemical activities, including energy pro-
duction and biogenesis of iron–sulfur (Fe–S) clusters1,
which are complexed into a variety of proteins as enzy-
matic cofactors. Improper synthesis of these Fe–S clusters
can lead to mislocalization or excessive deposits of iron
within tissues and cells, leading to pathological changes
and cellular dysfunction. A number of disorders have
been associated with the loss of Fe–S clusters and the
resulting accumulation of iron. As an example, Frie-
dreich’s Ataxia—one of the most common forms of
inherited hereditary ataxia—is caused by the unstable
expansion of a GAA trinucleotide repeat sequence within
the frataxin (FXN) gene. FXN encodes a mitochondrial
protein critical to the production of Fe–S clusters within
the mitochondrion2–4. Although the mechanism by which
the FXN protein synthesizes Fe–S clusters is poorly
understood, loss-of-function mutations result in elevated
iron levels within the mitochondria and mitochondrial
dysfunction5. This, in turn, leads to the onset of a host of
symptoms (usually before the age of 20), including ataxia6,
cardiomyopathy, and neurodegeneration in the cere-
bellum7. There is also evidence that elevated iron levels
may be at least partially responsible for the damage to
dopaminergic neurons that occurs in Parkinson’s disease8.
Finally, there is an entire class of rare, inherited neuro-
degenerative diseases referred to as NBIA (neurodegen-
eration with brain iron accumulation), which are
characterized by a progressive neurodegeneration pheno-
type linked with an abnormal and distinct accumulation of
iron in the basal ganglia9–12. Together, all of these lines of
evidence suggest that dysregulated iron metabolism may
be a recurring theme in neurodegenerative disorders.
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Ferredoxin reductase (FDXR) is a mitochondrial
membrane-associated flavoprotein. One of its functions is to
transfer electrons from NADPH to the two human ferre-
doxin proteins, FDX1 and FDX213,14. FDX1, in turn, reduces
cytochrome P450, giving FDXR an indirect but critical role in
steroid biosynthesis and drug metabolism pathways. Inter-
estingly, FDX2 appears to be the more critical of the two
ferredoxins in the iron–sulfur pathway, as deletion of FDX1
in HeLa cells does not elicit any defects in Fe–S cluster
biogenesis14, while mutation of FDX2 has been associated
with a mitochondrial muscle myopathy and severely
impaired activity of Fe–S proteins in mitochondria15. Fur-
thermore, while FDX1 is exclusively expressed in adrenal
gland, FDX2 is ubiquitously found in virtually all tissues14.
Thus, FDX1 (and indirectly, FDXR) is likely to participate in
the synthesis of bile acid, vitamin D, and steroid hor-
mones13,16–18, while FDX2 is likely involved in Fe–S cluster
biogenesis.
Having established the role of FDXR in Fe–S cluster
assembly, it is perhaps unsurprising to learn that knockdown
of FDXR activity leads to mitochondrial iron overload in cell
culture13. However, despite such tantalizing clues and a well-
defined biochemical function, the exact consequences of
FDXR mutation in patients have remained largely elusive.
Using data from a large number of families, we recently
demonstrated that biallelic mutations in the FDXR gene lead
to gait abnormalities and visual impairment19. In a parallel
analysis, we showed that mice possessing a naturally occur-
ring mutation in Fdxr presented with neurological abnorm-
alities, loss of visual acuity and gait abnormalities,
reminiscent of the phenotypes observed in patients. Enzy-
matic assays in both patient fibroblasts and in tissues from
Fdxr mutant mice indicated multiple biochemical and
metabolic consequences of FDXR mutation, including
reductions in ATP production and ETC complex activities,
along with a significant increase in the production of
reactive oxygen species (ROS)19. Furthermore, our follow-
up study showed that FDXR mutation is linked to
inflammation and gliosis in the CNS, providing clues as to
the possible mechanism of FDXR pathology20. Finally, an
independent study published by a separate group has
reported eight individuals in four different families carry-
ing loss-of-function mutations in FDXR who also pre-
sented with mitochondriopathy and peripheral sensory
neuropathies in the auditory and optic systems21, provid-
ing further corroboration of the neurodegenerative con-
sequences of FDXR mutation.
However, the mechanism by which FDXR mutation leads
to the observed neuropathy and optic atrophy is largely
unknown. Based on studies of Friedreich’s Ataxia and other
conditions in the iron–sulfur cluster synthesis pathway, iron
overload is a likely mechanism of FDXR pathogenesis. Here,
we show that abnormal iron accumulation is indeed pre-
valent in FDXR patient fibroblasts and in the tissues of
FdxrR389Q/R389Q mice, leading to molecular and cellular
dysfunctions such as reduced mitochondrial membrane
potential and optic transport defects. Together, these
results provide a better understanding of how loss of
FDXR function leads to the novel mitochondriopathy
associated with FDXR dysfunction and opens a potential
avenue to treat this group of patients.
Results
Fdxr mutations cause a progressive optic neuropathy and
optic transport defects in Fdxr−/− mice
The naturally occurring FdxrR389Q/R389Q mouse line22
harbors a homozygous R389Q missense mutation in Fdxr
that is allelic to the common human mutation p.R392W19.
To better characterize the optic neuropathy associated with
FDXR mutation, we examined the retina of FdxrR389Q/R389Q
mutant mice (hereafter referred to as “Fdxr−/−” mice) with
an imaging technique, optical coherence tomography (OCT),
that can acquire cross-sectional tomographic images of the
retina in vivo23,24. Although the optic disc appeared grossly
normal under bright-field examination, OCT scanning
revealed significantly thinner retinas in aged Fdxr−/− mice
(Fig. 1a). Quantitative measurements indicated that the
average thickness of the whole retina and ganglion cell
complex (GCC)—which includes the nerve fiber layer (NFL),
ganglion cell layer (GCL), and inner plexiform layer
(IPL)—were also decreased in Fdxr−/− compared with
Fdxr+/+ control mice at 10.5 months (Fig. 1b). In contrast,
outer retinal thickness was relatively normal.
To further extend this analysis, we performed a his-
topathological assessment of the retina. We counted
the retinal ganglion cell (RGC) layer nuclei in H&E-
stained paraffin sections of eyes from 3-week-old and
1-year-old Fdxr+/+ and Fdxr−/− mice. Retinal H&E-
stained sections displayed normal organization of ret-
inal structure, but thinner inner retinas and noticeable
retinal ganglion cell (RGC) loss in the GCL at 12 months
(Fig. 1c), in agreement with our previous data19. By contrast,
there was no significant difference in the number of RGC
layer nuclei between Fdxr+/+ and Fdxr−/− mice at 3 weeks
(Fig. 1d), suggesting RGC loss is a progressive, age-
dependent process.
Given the mounting evidence that FDXR mutation
causes optic atrophy and loss of retinal cells19, it is rea-
sonable to examine anterograde axonal transport within
mouse RGCs. In this experiment, cholera toxin subunit B
(CTB) conjugated with Alex-Fluor 488 was injected into
the eyes of 7-month-old Fdxr+/+ and Fdxr−/− mice. Two
days after injection, the brains were harvested, fixed, and
cryo-sectioned through the superior colliculi. As shown
in Fig. 2a, transport of the CTB-Fluor 488 marker from
the eye to the superior colliculi in the brain was greatly
reduced in the Fdxr−/− mutant mice, as compared with
their age-matched Fdxr+/+ controls. Electroretinography
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was also performed separately on the eyes of 4-month-old
Fdxr+/+ and Fdxr−/− mice. The results demonstrated
that both ocular photoreceptor rods and cones showed
decreased b-wave amplitude in response to light stimu-
lation (Fig. 2b), indicating that mutant retinal cells are
functionally compromised.
Fdxr mutation leads to an age-dependent loss of cells in
the CNS
To more closely examine the neurodegenerative
effect of Fdxr mutation in the mouse model, H&E
staining was performed on tissues from the liver,
muscle, spleen, and brain/cerebellum of 6-month-old
Fig. 1 Fdxr-mediated optic atrophy and RGC loss. a Optic disc and OCT scanning of P120 mice. The green line in optic disc images indicates the
position of OCT scanning. Scale bars: 100 μm. b Quantification of retinal thickness from OCT scanning images of retinas from Fdxr+/+ and Fdxr−/−
mice (*P < 0.05, **P < 0.01, ***P < 0.001); n= 14 retinal images derived from two animals, per genotype). c H&E-stained sagittal sections through the
optic disc show that the number of retinal ganglion cells (RGCs) in the Ganglion Cell Layer (green arrows) are markedly reduced in H&E sections of
eyes from 12-month-old Fdxr−/− mutant mice, as compared with Fdxr+/+ control mice. d H&E staining of retinal sections from mice at 3 weeks of age
indicates no difference in number of RGCs between Fdxr+/+ and Fdxr−/− animals.
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Fdxr−/− mice and compared with tissues from age-
matched Fdxr+/+ controls (Fig. 3a). As an age com-
parison, H&E staining was also performed on the kid-
ney, bone, muscle, and cerebellum tissue from 2-
month-old Fdxr−/− mice and from age-matched Fdxr+/
+ controls (Fig. 3b), as well as from the occipital lobe
(Supplementary Fig. S1B) and the spinal cord (Sup-
plementary Fig. S1A). In general, the most dramatic
cell reduction was observed in the mutant CNS sam-
ples, particularly in the cerebellar granular layer of 6-
month-old mice (Fig. 3a, white arrows). This cell loss is
likely related to the neurodegenerative effects that we
have demonstrated previously19,20. Examination of
tissue sections from the occipital lobe also revealed a
reduction in the number of cells in the visual cortex of
the Fdxr−/− mutants even at 8 weeks of age (Supple-
mentary Fig. S1B), which may further compound the
optic atrophy that we have previously observed19.
Fdxr mutation causes peripheral neuropathy associated
with axon degeneration and movement defects
Homozygous Fdxr−/− mice demonstrate stiffness in their
hindquarters by 7–8 weeks of age that progresses to a
severe reduction in ambulation (Fig. 4a–f), similar to the
phenotype observed in patients carrying the p.R392W
mutation. To more fully quantify the altered movement
behavior of these mice, we conducted comprehensive gait
analyses using a standard treadmill system. At 4–9 weeks of
age, significant differences in rear-gait measurements—
including impaired gait dynamics (swing and stance)
(Fig. 4a–d), rear sciatic functional impairments as measured
by the pawprint angle (Fig. 4e), and altered hindlimb base
support as measured by increased hindpaw width (Fig. 4f)—
were observed across both sexes in Fdxr−/− homozygous
mice relative to age- and sex-matched Fdxr+/+ controls. By
10–13 weeks of age, advanced gait impairment prevented
most Fdxr−/− homozygous mice from performing these
Fig. 2 Fdxr mutation causes functional defects in retinal neurons. a Anterograde axonal transport of mouse retinal ganglion cells (RGCs) was
measured in the mouse eyes. Seven-month-old Fdxr+/+ control and Fdxr−/− mutant mice were anesthetized with an inhalation of 2.5% isoflurane.
Brains were cryo-sectioned through the superior colliculi with a thickness of 50 µm. Transport of CTB-Fluor 488 from the eye to the superior colliculi in
the brain was greatly reduced in the Fdxr−/− mutant mice, as compared with the transport in the Fdxr+/+ control mice. Scale bars: 100 μm.
b Electroretinography was performed in 4-month-old Fdxr+/+ and Fdxr−/− mouse eyes. After light stimulation, both ocular photoreceptor rods and
cones showed decreased b-wave amplitude in the Fdxr−/− mutants relative to control mice.
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tests, confirming that Fdxr mutation leads to severe defects
in the control of movement behavior.
Six-month-old Fdxr−/− mice also display enhanced
hindlimb-clasping reflex and muscle atrophy, indicative of
potential peripheral neuropathy (Supplementary Figs. S2A
and S2B). In many human peripheral neuropathies,
degeneration is associated with muscle atrophy and lower
extremity dysfunction. We examined peripheral nerve
conduction in Fdxr−/− mice by acquiring compound
muscle action potentials (CMAPs) from the lateral gastro-
cnemius muscle during direct electrical stimulation of the
exposed sciatic nerve in vivo. Based on recorded electro-
myography (EMG) waves (Fig. 4g), conduction velocity
(CV) was decreased in Fdxr−/− mice at 6 months compared
with normal littermates (Fig. 4h, i), suggesting that
myelination defects may underlie this aspect of Fdxr
pathology.
Interestingly, our results also showed an observable
increase in the number of cells in the spinal cord sections of
eight-week old Fdxr−/− mutant mice (Supplementary Fig.
S1A), as well as a significant increase in the cell number in
the superficial area (Supplementary Fig. S1C), middle area
(Supplementary Fig. S1D), and deeper area (Supplementary
Fig. S1E) of the cerebral cortex. Given the clear reduction in
cell number observed in mutant CNS tissue by 6 months of
age (Fig. 3a), it is likely that the increased cell number
observed in 8-week-old mutant mice represent peripheral
immune cells that have been recruited as a result of the
neurodegenerative process itself. This phenomenon has been
fairly well-documented in the literature25, and would not be
expected to stave off neuronal cell loss in the long term.
Thus, the initial increase in cell number would not be
expected to be maintained with age, leading to the dramatic
loss of CNS cells observed in older mouse tissues.
Fdxr mutation disrupts iron metabolism, leading to iron
accumulation
Despite its well-characterized role in iron metabolic
pathways, the in vivo role of FDXR in iron metabolism
remains relatively unexplored. To test the hypothesis that
FDXR mutation modulates iron metabolism, total cellular
iron and iron in the mitochondrial fraction were measured
using the QuantiChrom iron assay. In patient fibroblasts,
we found that FDXR mutations lead to a dramatic accu-
mulation of iron in mitochondrial-specific extracts (Fig. 5a).
This effect was recapitulated in the mouse model (Fig. 5b),
Fig. 3 Pathology assessment of tissues from Fdxr mutant mice. a H&E staining of Fdxrmutant mouse tissues from the liver, muscle, spleen, and brain/
cerebellum from 6-month-old Fdxr−/− mice as compared with Fdxr+/+ control mice. The cerebellar granular layers for the mutant and control samples are
indicated with white arrows. In general, the cerebellar granular layer of the mutant sample shows a reduced volume (relative to the other cerebellar layers)
than what is observed in the control sample. b H&E staining of tissues from the kidneys, bone, and muscle, and cerebellum from 2-month-old Fdxr−/− mice
as compared with Fdxr+/+ control mice.
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where we also demonstrated that Fdxrmutation causes iron
accumulation in mitochondrial extracts from multiple tis-
sues (including the brain, liver, heart, and muscles). Iron
accumulation in the mouse model was further confirmed by
Prussian blue staining of Fdxr−/− mouse tissues (at the age
of 10.5 months) (Fig. 5e, f). Interestingly, the QuantiChrom
assay showed that cytosolic extracts as a whole possess no
discernible difference in iron levels between Fdxr−/−
mutant and Fdxr+/+ control samples (Fig. 5c, d). Taken
together, these results conclusively demonstrate that FDXR
dysfunction leads to mitochondria-specific iron accumula-
tion across multiple organ systems.
Fdxr mutations compromise the mitochondrial membrane
potential
The role of iron accumulation in mitochondria asso-
ciated with FDXR mutations is not fully understood.
Previously, mutations of FDXR were associated with
multiple biochemical and metabolic abnormalities,
including reductions in ATP production, ETC complex
activities, and oxygen consumption rates, along with a
significant increase in the production of ROS19.The defi-
ciency in some complexes could be explained by abnor-
mal iron–sulfur synthesis, as iron–sulfur is the cofactor
for those complexes. In support of this model, frataxin
mutation has been shown to cause an increase in ROS
production, as well as a decrease in mitochondrial
membrane potential (ΔΨm) in Friedreich’s ataxia
model26. Iron accumulation may also play a more direct
role in the process of mitochondrial dysfunction, as iron
overload has been reported to directly induce mitochon-
drial membrane depolarization and increased ROS pro-
duction in mitochondria isolated from rat cardiac cells27.
To test whether the iron accumulation in our animal
model is associated with changes in mitochondrial
membrane potential, ΔΨm was measured in our patient
fibroblasts and Fdxr−/− mouse embryonic fibroblasts
using the cell-permeable fluorescence probe TMRE (tet-
ramethylrhodamine, ethyl ester), which accumulates in
mitochondria as a result of their high membrane poten-
tial. The fluorescence intensity at Ex/Em= 550/580 was
recorded to delineate the relative ΔΨm level of mutant
and control cell lines. As shown in Fig. 6a, c, the ΔΨm in
the mutant cell lines from patients (Fig. 6a) and the
Fdxr−/− MEF cells (Fig. 6c) were consistently ~15–20%
lower than the ΔΨm observed in their respective control
cell lines. In contrast, the ΔΨm in mutant and patient
cells in the presence of CCCP (carbonyl cyanide 3-
chlorophenylhydrazone) were comparable with those
measured in the control cell lines (Fig. 6b, d). Together,
these results support the idea that the accumulation of
iron associated with loss of FDXR affects the normal
function of mitochondria and comprises the ETC, as we
demonstrated previously19.
Discussion
Several important implications are suggested by our
results, all of which help to unify the previously disparate
observations about the mechanism of FDXR-based patho-
genesis. Most importantly, the results of our iron metabo-
lism assay confirm that FDXR deficiency markedly increases
the level of mitochondrial iron in both human and mouse
tissues (Fig. 5). This is perhaps not so surprising since iron
toxicity has been previously considered as a possible
pathogenic contributor to FDXR phenotypes. However, the
iron accumulation we have observed here has not been
previously reported in the nervous system in the Fdxr−/−
mutant mouse model21,28, and provides the first direct
evidence that mitochondrial iron accumulation occurs in
the nervous system upon Fdxr mutation. Total iron levels
are also upregulated in the fibroblasts of FDXR patients.
Moreover, Prussian blue staining confirms that mitochon-
drial levels are increased in the brain, liver, heart, and
muscle of Fdxr−/− mutant mice, indicating that a similar
pathway is also activated in our mouse model and may
contribute to the pathogenic mechanism of FDXR. The fact
that iron accumulation is observed in the brain as well as in
liver, heart, and muscle tissue also suggests that this
pathogenic mechanism may involve both the CNS as well as
non-neuronal tissue. This broad pattern of iron accumula-
tion in multiple tissues is reminiscent of the iron accumu-
lation observed in the heart, liver, and spleen of patients
with Friedrich’s ataxia29–31, further suggesting that FDXR
dysfunction may share at least some mechanistic similarities
with frataxin dysfunction (perhaps through their shared
pathway component FDX2).
(see figure on previous page)
Fig. 4 Gait abnormalities and peripheral nerve conduction defects of FdxrR389Q/R389Q mutant mice relative to wild-type (WT) mice.
Significant impairments in rear-gait dynamics (slower swing times and shorter time in stance position) were observed in Fdxr mutants relative to WT
controls independent of sex (b, d), whereas front-gait dynamics appeared unaffected (a, c). Altered rear-gait dynamics in FdxrR389Q/R389Q were
associated with abnormal hindpaw position and significantly impaired sciatic function as measured by pawprint angle (e) and impaired hindlimb
base support as measured by increased hindpaw width (f). To confirm the underlying neurophysiology of these behavioral defects, CMAP recordings
were taken from sciatic nerves of Fdxr+/+ (black) and Fdxr−/− (red) mice at 2 months of age (g). Arrows indicate onset of electrical stimulation of the
sciatic nerve during recording. Conduction velocities (CVs) were measured from recorded waves using a 2 mA (h) or 4 mA (i) electrical stimulation of
the sciatic nerve (n= 16 for Fdxr+/+ and Fdxr−/− mice; P < 0.001). Data are representative of two independent experiments.
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Optic atrophy is one of the most striking phenotypes in
human patients carrying biallelic FDXR mutations, and
our analysis of the Fdxr−/− mutant mice only serves to
further confirm and clarify this phenomenon. Age-
dependent RGC degeneration was confirmed to be the
major pathological feature of Fdxr-related optic atrophy
in mice (Fig. 1). Specifically, our results revealed a sig-
nificantly reduced thickness in the whole retina and in the
ganglion cell complex of adult Fdxr−/− mutant mice
(likely associated with RGC loss and optic nerve degen-
eration) (Fig. 1), and this loss has been confirmed at the
functional level by electroretinography analysis (Fig. 2b).
It is unclear if a corresponding loss of photoreceptor cells
contributes to this phenotype, as the overall thickness of
the outer retina (which contains the photoreceptors) did
not appear to be affected. It is possible, however, that
photoreceptor function could be compromised without
resulting in a loss of the cells themselves. Overall, these
(see figure on previous page)
Fig. 5 FDXR mutation regulates iron metabolism. Iron levels (Fe2+ plus Fe3+) were measured by QuantiChrom iron assay in extracts from control
and patient fibroblasts carrying FDXRR392W/R392W or FDXRG443S/F51L mutations (a, c), and in extracts from Fdxr−/− mutant mice and Fdxr+/+ littermates
(b, d). Iron levels in mitochondrial extracts (a, b) were reduced in FDXR mutant cells and tissues. In contrast, cytoplasmic extracts showed no
significant differences between FDXR mutant cells/tissues and their corresponding controls (c, d). e Fdxr deficiency leads to iron overload at the age
of 10.5 months in mice. Tissues from Fdxr−/− mutant mice and Fdxr+/+ littermates were stained with Prussian blue to measure iron accumulation. The
results are shown for the liver, heart, muscle, kidney, and spleen. f Prussian blue staining was also carried on various brain tissues from Fdxr−/− and
Fdxr+/+ mice. The results show increased iron levels in the cerebellum, cortex, lateral ventricle, thalamus, and olfactory bulb.
Fig. 6 FDXR mutation leads to a reduction in mitochondrial membrane potential. a The mitochondrial membrane potential (ΔΨm) was
measured in patient fibroblasts with FDXRR392W/R392W or FDXRG443S/F51L mutations and control fibroblasts, using a TMRE-based assay system. ΔΨm was
determined according to the relative fluorescence intensity at Ex/Em= 550/580, in the absence of 10 µM of carbonyl cyanide 3-
chlorophenylhydrazone (CCCP). b Mitochondrial membrane potential of the cell lines from panel a, as measured in the presence of 10 µM of
carbonyl cyanide 3-chlorophenylhydrazone (CCCP), is shown as a control. c Mitochondrial membrane potential, as determined in mouse embryonic
fibroblasts (MEFs) from Fdxr−/− mutant mice and Fdxr+/+ control littermates. d Mitochondrial membrane potential of the cell lines from panel d, as
measured in the presence of 10 µM of CCCP, is shown as a positive control. The average of three to five determinations is shown for each cell line.
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results are strikingly similar to the results we observed in
our previous findings in Slc25a46 mutant mice, which
showed a similar pattern of optic atrophy and RGC loss to
the one that has been observed with Fdxr−/− mutants32,33.
Perhaps one of the most interesting parallels between the
Slc25a46 mice and the Fdxr−/− mice is the axonal
transport defects observed in the RGCs of Fdxr−/−
mutants (Fig. 2a), which mirrors the mitochondrial
transport defects observed in Slc25a46−/− Purkinje
cells33. It will be interesting to determine if there are other
commonalities in the visual impairment phenotype
between these two genetic models, or with other more
common forms of optic neuropathy such as diabetic
retinopathy or open-angle glaucoma.
The optic atrophy phenotype brings up the related issue
of neurodegeneration in the FDXR disease model. EMG of
the lateral gastrocnemius muscle surrounding the sciatic
nerve in adult Fdxr−/− mice showed reduced CAMPs and
CVs (Fig. 4), which indicates degeneration in the axons of
distal sciatic nerves. The reduction of CV in Fdxr−/−
mutant mice could be secondary to demyelination, which
is likely to be the result of axon degeneration induced by
compromised mitochondrial function. Our previously
published data also show that Fdxr mutation causes
inflammation and gliosis in the CNS20, and this (com-
bined with iron overload) may cause neurodegeneration
and contribute to the pathogenesis of impaired motor
coordination in Fdxr−/− mice (Fig. 4). It is particularly
curious that iron particles are not only deposited inside
the neuronal cell bodies, but are also present in the
extracellular space (Fig. 5e, f) where they may serve to
activate the glial cells that mediate chronic inflammation.
How iron accumulation leads to an increase in neurode-
generation has remained unclear until now; however,
when combined with our previous report20, these results
suggest that iron accumulation may enhance inflamma-
tion and activation of glia (particularly in the brain), and
that this excess inflammation may promote neurodegen-
eration in Fdxr mutants. There is already some pre-
cedence for this in mouse models of type I and type II
diabetes. These mice, which display retinal degeneration
similar to human diabetic retinopathy cases, have also
been shown to exhibit both increased iron accumulation
and increased inflammatory signals in the retina34. It is
likely that iron is the agent that induces the inflammation
and cell death, as subretinal injections of iron have been
previously shown to induce cell death in the RPE layer of
the retina via an explicitly inflammatory mechanism35.
However, there may be other underappreciated factors at
play as well. For example, actin aggregation has also been
associated with iron accumulation and inflammation in
the brain tissue of patients with primary dystonia36.
On the other hand, it has also been shown that microglia
can influence iron accumulation in neurons through
secretion of the peptide hormone hepcidin, a process that
is itself induced by the neuroinflammation mediator
fractalkine37. Thus, further study is warranted in all
models of neurodegenerative disease to disentangle the
complex relationship between inflammation, iron accu-
mulation and cell death, and to clarify any underlying
factors that may unite this broad class of disorders.
The dramatic phenotypes caused by FDXR mutation
shine new light on the importance of the human ferre-
doxin pathways. Humans have one ferredoxin reductase
gene (FDXR)38, which is a FAD-dependent enzyme that
reduces FDX1 and FDX2 using NADPH as the electron
donor13,16. Depletion of FDXR diminishes Fe–S cluster
assembly and causes mitochondrial iron overload13,
indicating that FDXR has a crucial role in Fe–S cluster
biogenesis in human cells. The surprising number of
patient families with FDXR mutations that have been
discovered in such a short period of time raises the pos-
sibility that the FDXR/FDX1/FDX2 pathway may lie
behind many cases of optic atrophy and ataxia with no
previously identified cause. In support of this hypothesis,
biallelic mutations in the FDX2 gene (FDX1L) have
already been identified in patients with metabolic myo-
pathy with deficiencies in various complexes of the ETC,
suggestive of mitochondrial Fe–S-related defects15. More
recently, a case report of individuals from two unrelated
Brazilian families carrying the same homozygous muta-
tion in FDX2 (c.431 C > T, p.P144L) has provided evi-
dence of optic atrophy, myopathy, and axonal neuropathy
linked to this variant39. Given these facts, we believe that
all members of the ferredoxin pathway merit further
investigation by the field as a potentially underappreciated




All procedures involving mice were approved by either
the Institutional Animal Care and Use Committee of
Cincinnati Children’s Hospital Medical Center or The
Jackson Laboratory’s Institutional Animal Care and Use
Committee and performed in accordance with the
National Institutes of Health guidelines for the care and
use of animals in research. The strain used for this study
was B6; 129S-Fdxrm1J Otop3m1J/GrsrJ (The Jackson
Laboratory, Stock #026096). This strain was previously
shown to exhibit an abnormal, recessive gait phenotype,
and harbors a missense (autosomal recessive) mutation in
the Fdxr gene resulting in a p.R389Q change in the Fdxr
protein22. Protein alignment also shows that this amino
acid change is located at the same position as mutation
R392W in the human ortholog. Although these mice also
carry a linked homozygous variant of uncertain clinical
significance in the 5′ untranslated region of Otop3, it is
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likely not contributing to the phenotype because mice
with a targeted deletion of the Otop3 gene show increased
startle reflex and oligodactyly.
Cell culture and generation of stable FDXR overexpressing
cell line
Fibroblasts derived from patients with FDXRR392W/R392W
and FDXRG443S/F51L genotypes (as well as control fibro-
blasts) were grown in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, Thermo Fisher Scientific; Grand Island,
NY) supplemented with 10% fetal bovine serum at 37 °C
with 5% CO2, as described previously
19. MEFs derived
from mice were grown in DMEM (Gibco, Thermo Fisher
Scientific; Grand Island, NY) supplemented with 10% fetal
bovine serum at 37 °C with 5% CO2. WT human FDXR
cDNA was obtained from Addgene (pTRE-FDXR WT,
transcript variant 3, NM_001258012.3) and the stable
FDXR overexpressing cell lines were generated, as shown
previously19.
Determination of iron levels
Fresh cells or mouse tissue were homogenized in 5×
volumes of iron assay buffer using a Dounce homogenizer
sitting on ice. Homogenized samples were centrifuged at
16,000×g for 10 min, and the supernatant was then col-
lected for the assay (Iron Assay Kit, Abcam, ab83366).
The volume of each assay solution was 100 µl (50 µl from
each sample combined with 50 µl of the iron assay buffer).
In order to determine total iron (II+ III) levels, 5 µl of
iron reducer was added to each sample, which were then
mixed and incubated at 25 °C for 30 min. In total, 100 µl
iron probe was added to each well, mixed, and incubated
at 25 °C for 60 min while protected from light. At the end
of 60min, the output was recorded immediately on a
spectrophotometric microplate reader (OD 593 nm).
Prussian blue staining
Mice were euthanized in age-matched groups and per-
fused with 0.9% saline. Frozen tissue sections fixed with 4%
PFA were placed in working Iron Stain Solution (Sigma-
Aldrich; St. Louis, MO, HT20-1KT). The staining solution
consisted of an equal volume of potassium ferrocyanide
solution and hydrochloride acid solution. Tissues were
stained for 10min, rinsed in deionized water, and stained
in working pararosaniline solution (1ml of pararosaniline
solution added to 50ml water) for 5min. The stained
tissues were rinsed in deionized water, rapidly dehydrated
through alcohol and xylene, and then mounted.
Mitochondrial membrane potential assay
Human fibroblasts or MEFs at a density of 5 × 103 were
plated to each well of a 96-well plate, and cultured in an
incubator overnight to allow cell attachment. The next
day, the culture medium was aspirated from the plate, and
100 µl of fresh medium was added. For the positive con-
trol, CCCP (carbonyl cyanide 3-chlorophenylhydrazone)
was added to the control wells for a 50 µM final con-
centration, and the cells were incubated at 37 °C for
15min. In total, 10 µl of 2 µM TMRE (tetra-
methylrhodamine ethyl ester perchlorate) labeling solu-
tion was added to each well to get a final concentration of
200 nM, and the plates were placed in an incubator (37 °C,
5% CO2) for 20 min. The solution was aspirated from each
plate, followed by three washes with warm 1× PBS, and
then the addition of 100 µl/well 1× PBS to the plate.
Samples were analyzed on a Synergy HTX Multi-Mode
Microplate Reader (BioTek Instruments, Inc.; Winooski,
Vermont, United States), with excitation at 550 nm and
emission at 580 nm (Cell Signaling Technology, #13296).
Anterograde axonal transport assay in mouse retinal
ganglion cells (RGCs)
Seven-month-old B6;129 S Fdxr+/+ or Fdxr−/− mutant
mice were anesthetized with an inhalation of 2.5% iso-
flurane. Using a Hamilton syringe attached with a 33-G
needle, 1 µl of 1% cholera toxin subunit B (CTB) con-
jugated with Alex-Fluor 488 (green) was injected into the
left eye of each mouse. The mice were euthanized 2 days
later. The mice were then perfused with 4% PFA, and the
brains were harvested. The brains were dehydrated in 30%
sucrose overnight, and then embedded in OCT. The
brains were cryo-sectioned through the superior colliculi
with a thickness of 50 µm. The consecutive sections were
viewed and imaged under a fluorescent microscope.
In vivo imaging using OCT
Mice at 10.5 months of age were anesthetized with a
mixture of xylazine (6 mg/kg) and ketamine (100 mg/kg).
Pupils were dilated with a topical drop of cyclomydril
(Alcon Laboratories, Fort Worth, TX). Two minutes after
pupil dilation, lubricating eye drops (Alcon Laboratories)
were applied to the cornea. Spectral domain OCT with
the guidance of bright-field live fundus imaging was
performed using an image-guided OCT system (Micron
IV, Phoenix Research Laboratories, Pleasanton, CA)
according to the manufacturer’s instructions. The ven-
dor’s image acquisition software was used to generate
fundus images and OCT scans. The vendor’s software
(InSight) was then used to measure thicknesses of retinal
layers (NFL+ IPL+ INL and outer retinal layer) and
entire retinas.
Histological studies
Mice were euthanized in age-matched groups and per-
fused with 0.9% saline. Tissues were fixed in 10% formalin,
then embedded in paraffin, sectioned, and stained with
hematoxylin and eosin (H&E). H&E-stained tissues were
analyzed by light microscopy. Images were obtained
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under light microscopy (BX63; Olympus Corporation;
Center Valley, PA).
Gait analysis
Gait analysis was performed by the Mouse Neurobe-
havioral Phenotyping core at The Jackson Laboratory
using the Cleversys ExerGait treadmill system (CleverSys
Inc.) equipped with Treadscan software. Following accli-
mation, test subjects were placed into the treadmill
chamber, and the treadmill was slowly increased to
16.7 cm/s. A highspeed camera positioned below the
treadmill belt facing the ventral surface (belly) recorded
activity of paw placement over an ~5min duration. Gait
measures were defined by the software parameters (www.
cleversysinc.com). For analysis, the data for left and right
paws were averaged for front and hindpaw gait dynamics.
A total of 48 mice (8 mice of each sex/genotype) were
tested in three cohorts at two time points, 4–9 weeks of
age and 10–13 weeks of age. All technicians were blinded
to genotype during testing and analysis. Mice that failed to
maintain gait at 16.7 cm/s were excluded.
Electroretinography (ERG)
A total of 41 mice (at least 6 mice per sex per genotype)
were evaluated by electroretinography at 4 months of age.
All technicians were blinded to genotype during testing.
Following a 2–5 h dark adaptation, mice were anesthe-
tized with an intraperitoneal injection of xylazine (80 mg/
kg) and ketamine (16 mg/kg) in normal saline. Dilation of
pupils was achieved with one drop of Atropine and 1%
Cyclomydril. Rod-mediated ERGs were recorded with the
responses to short-wavelength flashes over 4.0-log units
to the maximum intensity by a photopic stimulator.
Cone-mediated ERGs were recorded with white flashes
after 8 min of complete light adaptation. The signals were
sampled at 0.8-ms intervals, and were reported as
averages40.
Compound muscle action potential (CMAP) recording
Mice were first anesthetized with an intraperitoneal injec-
tion of 50mg/kg sodium phenobarbital. The lateral gastro-
cnemius muscle was then exposed from the knee to about
4mm above the ankle. The sciatic nerve was exposed near
the biceps femoris muscle. Mylar-coated steel recording
wires (California Fine Wire) were implanted into the lateral
gastrocnemius muscles, and reference wires were inserted
under the skin near the base of the tail. A concentric bipolar
stimulating electrode was placed on the sciatic nerve and
used for electrical activation.
CMAPs were amplified, recorded with a Micro 1401
data acquisition unit, and analyzed offline with
Spike2 software (Cambridge Electronic Design, Cam-
bridge, UK). A 2- to 4-mA electrical stimulation of the
sciatic nerve immediately proximal to the tibial, sural, and
common peroneal branches was employed via a stimulus
isolation unit (WPI) connected to the Micro 1401. After
recording, the sciatic nerve was axotomized. The proximal
end of the sciatic nerve was stimulated to ensure that
CMAPs were generated from direct nerve stimulation.
CMAP CV, amplitude, and duration were calculated from
each stimulation paradigm. The average stimulation of the
sciatic nerve for each paradigm was obtained and aver-
aged across animals.
Statistical analysis
Results are presented as mean values ± SD or SEM.
Graphical illustrations and significance were obtained with
GraphPad Prism (GraphPad Software, San Diego, CA, USA)
using Student’s t test or multiple comparison ANOVA,
followed by Bonferroni or Dunnett post hoc tests (accord-
ing to the sample sets), unless otherwise stated. P < 0.05 was
considered statistically significant (*P < 0.05; **P < 0.01;
***P < 0.001).). For all statistical tests, the data were con-
firmed to meet all of the relevant assumptions of the test,
including normal distribution and homoscedasticity. The
sample sizes were chosen to ensure sufficient statistical
power based on previous experience in the lab. No method
of randomization was used to determine how samples/
animals were allocated to experimental groups.
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